Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial is a research paper published in eLife (2023). On theSindex it has a DataRank of 1.0. It has been cited 33 times, with 21 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.529
From this paper's citation signal
Citation Network Contribution
0.494
From 18 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 21 citers.
National Cancer Institute
Grant: 3P30CA013330-49S3
Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
National Cancer Institute
Grant: Community Oncology Outreach Program 2UG1CA189859-06
Leukemia & Lymphoma Society
Grant: IRVBC0004-22
Centers of Excellence for Influenza Research and Surveillance
Grant: HHSN272201400008C
Centers of Excellence for Influenza Research and Response
Grant: 75N93021C00014
Collaborative Influenza Vaccine Innovation Centers
Grant: 75N93019C00051
National Cancer Institute
Grant: 75N91019D00024
NCI NIH HHS
Grant: UG1 CA189859
NCI NIH HHS
Grant: P30 CA013330
National Institutes of Health
Grant: 2UG1CA189859-06
MINORITY-BASED COMMUNITY ONCOLOGY PROGRAM
FWCI
5.86
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals